Mankind Pharma
Mankind Pharma Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Mankind Pharma Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Mankind Pharma Ltd trades at a P/E of 51.46× and P/B of 6.03×.
Valuation
Profitability
Growth
Financial Health
Mankind Pharma Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Mankind Pharma Ltd, switchable between annual and quarterly views, consolidated or standalone.
Mankind Pharma Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹98,228.37 Cr and reported EPS of ₹46.27.
| Period | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Revenue from Operations | 8,749 | 10,335 | 12,207 | 14,278 |
| Other Income | 129 | 281 | 537 | 359 |
| Total Income | 8,878 | 10,616 | 12,744 | 14,636 |
| Cost of Goods Sold (COGS) | 2,914 | 3,210 | 3,489 | 4,052 |
| Gross Profit | 5,836 | 7,125 | 8,718 | 10,226 |
| +Operating Expenses | 3,935 | 4,590 | 5,700 | 6,608 |
| EBITDA | 1,901 | 2,535 | 3,018 | 3,617 |
| +Non-Operating Expenses | 370 | 432 | 1,051 | 1,396 |
| Profit Before Tax (PBT) | 1,659 | 2,384 | 2,504 | 2,321 |
| +Tax Expense | 362 | 458 | 510 | 395 |
| Profit After Tax (PAT) | 1,310 | 1,942 | 2,011 | 1,938 |
| Earnings Per Share (EPS) | 32.00 | 47.75 | 48.26 | 46.34 |
| Diluted Shares Outstanding (Nos.) | 40 | 40 | 41 | 41 |
| +Additional Disclosures | 10,171 | 11,477 | 13,758 | 16,332 |
| Sales Growth % | — | 18.12 | 18.12 | 16.96 |
| YoY Sales Growth % | — | 18.12 | 18.12 | 16.96 |
| Material Cost % | 21 | 18 | 17 | 16 |
| Employee Cost % | 22 | 22 | 22 | 22 |
| Other Cost % | 23 | 22 | 25 | 24 |
| OPM % | 22 | 25 | 25 | 25 |
| Tax % | 22 | 19 | 20 | 17 |
| Profit Growth % | — | 48.26 | 3.57 | -3.63 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 1,575 | 2,137 | 2,397 | 2,731 |
Mankind Pharma segment analysis: revenue and profit mix.
Disclosed business segments at Mankind Pharma with their share of revenue and profit, switchable between consolidated and standalone reporting.
Mankind Pharma discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Mankind Pharma Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Mankind Pharma Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Mankind Pharma Ltd's investment case rests on 9 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Mankind Pharma demonstrates robust quarterly sales growth, with a 24.5% increase, signaling strong demand for its products and effective market penetration strategies, which is a positive indicator for future revenue streams.
The company maintains a substantial promoter holding of 72.7%, reflecting high confidence from its founders in the long-term prospects and stability, potentially reducing risks associated with management shifts.
Mankind Pharma exhibits healthy returns, with a Return on Equity (ROE) of 14.7% and Return on Capital Employed (ROCE) of 16.0%, showcasing efficient utilization of capital and assets to generate profits for shareholders.
A high operating profit margin (OPM) of 24.7% highlights the company's strong pricing power and effective cost management, which are crucial for sustained profitability and resilience in a competitive market.
FII and DII holdings have significantly increased from 4.18% to 12.83% and 4.65% to 11.91% respectively since June 2023, indicating growing institutional investor confidence in the company's future.
What can break it.
A notable concern is the recent -17.6% decline in quarterly profit variability, suggesting potential challenges in maintaining profit momentum. Investors should carefully analyze the underlying reasons for this downturn.
Mankind Pharma's high price-to-earnings (P/E) ratio of 53.40, which is above many peers, suggests the stock might be overvalued compared to its earnings, warranting caution and thorough valuation analysis.
The company's debt-to-equity ratio stands at 0.59, indicating a moderate level of debt. While not alarmingly high, it's a factor to monitor, especially considering the recent profit variability and market conditions.
Promoter holding has decreased from 76.5% in June 2023 to 72.7% currently, signaling a potential shift in ownership structure. Investors should investigate the reasons behind this reduction and its implications.
The stock's current price of 2444 is significantly below its 52-week high of 3055, indicating recent underperformance or a market correction, which could signal investor apprehension or changing sentiment.
What would change my mind.
Trim if P/E re-rates above 67. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 38.61. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Mankind Pharma Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Mankind Pharma Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Mankind Pharma Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Mankind Pharma Ltd — derived from the live tape, not yesterday's close.
Mankind Pharma Ltd last traded at ₹2,381.1 with an intraday range of ₹2,368.1–₹2,419 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹2381.10| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2512.50 | +131.40 | +5.52% |
| R3 | 2461.60 | +80.50 | +3.38% |
| R2 | 2440.30 | +59.20 | +2.49% |
| R1 | 2410.70 | +29.60 | +1.24% |
| PIVOT | 2389.40 | 8.30 | 0.35% |
| CURRENT | 2381.10 | — | — |
| S1 | 2258.00 | -123.10 | -5.17% |
| S2 | 2308.90 | -72.20 | -3.03% |
| S3 | 2338.50 | -42.60 | -1.79% |
| S4 | 2359.80 | -21.30 | -0.89% |
MANKIND is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: 2400 ~ 2419
Trading Inside opening range
Mankind Pharma Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Mankind Pharma Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Mankind Pharma Ltd stood at 55.6% of traded volume, against a 20-day average of 49.8%.
Mankind Pharma announcements: results, concalls, ratings, M&A.
Filings Mankind Pharma sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Mankind Pharma files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 160 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Mankind Pharma Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Mankind Pharma Limited has informed the Exchange about Link of Recording
Copy of Newspaper Publication
Mankind Pharma Limited has informed the Exchange about Copy of Newspaper Publication
Credit Rating- New
Mankind Pharma Limited has informed the Exchange about Credit Rating- New
Sale or disposal
Mankind Pharma Limited has informed the Exchange about Sale or disposal
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Mankind Pharma dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Mankind Pharma has declared, sequenced by announce and record date.
Mankind Pharma corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Mankind Pharma Ltd: business, sector, key facts.
What Mankind Pharma Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Mankind Pharma Ltd operates in the Healthcare, listed as NSE: MANKIND, BSE: 543904.
Mankind Pharma is a prominent Indian pharmaceutical and consumer healthcare company established in 1991 and headquartered in New Delhi. Its core business revolves around the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations and consumer healthcare products, primarily within India but with an expanding international presence. The company's pharmaceutical offerings cater to a wide spectrum of therapeutic areas, encompassing acute and chronic conditions.
A significant portion of Mankind Pharma's pharmaceutical portfolio addresses major health concerns such as infections, cardiovascular issues, gastrointestinal problems, diabetes, dermatological conditions, pain management, neurological disorders, and respiratory illnesses. This extensive range reflects a commitment to providing treatments for a broad array of health needs. The company's strength lies in its ability to develop and manufacture pharmaceuticals across various therapeutic classes.
Beyond pharmaceuticals, Mankind Pharma also has a robust consumer healthcare division. This segment focuses on products designed for over-the-counter use and self-care. Key offerings include male condoms under the Manforce brand, pregnancy detection kits (Prega News), emergency contraceptives (Unwanted-72), antacids (Gas-O-Fas), nutritional supplements, and acne treatments (AcneStar). These consumer products demonstrate the company's commitment to addressing a wider range of health and wellness needs for consumers.
Mankind Pharma's business activities extend beyond its core pharmaceutical and consumer healthcare operations. The company is involved in the trade and export of pharmaceutical and healthcare products, indicating a global reach. Furthermore, it engages in the manufacturing of various materials, including packaging materials, bulk drugs, and consumer goods. This diversification also includes ventures into real estate, leasing, hospitality, and IT services, suggesting a broader business strategy beyond healthcare.
In summary, Mankind Pharma's business model is characterized by its diversified portfolio spanning pharmaceuticals for various therapeutic areas, a substantial consumer healthcare division, and additional ventures in related sectors. The company's success stems from its integration of research, development, manufacturing, and marketing capabilities, coupled with its diverse product offerings and strategic diversification into other businesses.
Questions investors ask about Mankind Pharma Ltd (MANKIND).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Mankind Pharma Ltd (MANKIND)?
The current share price of Mankind Pharma Ltd (MANKIND) is ₹2,381.1. Today, the stock has gained by ₹8.40 (0.35%), trading in a range of ₹2,368.1 to ₹2,419. The stock opened at ₹2,419 with a trading volume of 2,86,099 shares.
02Is Mankind Pharma Ltd stock a good investment for long-term?
Mankind Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹98,228.37 crores, P/E ratio of 51.46, ROE of 12.45%, and ROCE of 16.00%. The dividend yield stands at 0.08%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Mankind Pharma Ltd stock?
The 52-week high price of Mankind Pharma Ltd (MANKIND) is ₹0, while the 52-week low is ₹0. Currently trading at ₹2,381.1, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Mankind Pharma Ltd stock at the current price?
Whether to buy Mankind Pharma Ltd stock at ₹2,381.1 depends on multiple factors. The stock is currently trading with a P/E ratio of 51.46 and P/B ratio of 6.03. Today's performance shows a gain of 0.35%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Mankind Pharma Ltd and when is the next dividend?
Mankind Pharma Ltd offers a dividend yield of 0.08%, which means for every ₹100 invested at the current price of ₹2,381.1, you can expect to receive approximately ₹0.08 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Mankind Pharma Ltd?
Mankind Pharma Ltd's key financial metrics include: P/E Ratio: 51.46, P/B Ratio: 6.03, ROE: 12.45%, ROCE: 16.00%, Dividend Yield: 0.08%, EPS: ₹46.27, Book Value: ₹395.2, and Debt-to-Equity: 38.11. The company's market cap stands at ₹98,228.37 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Mankind Pharma Ltd stock performing today in the market?
Mankind Pharma Ltd stock opened at ₹2,419 and is currently trading at ₹2,381.1, showing a gain of ₹8.40 (0.35%). The intraday high is ₹2,419 and low is ₹2,368.1. The trading volume stands at 2,86,099 shares, indicating moderate market participation today.
08What is the P/E ratio of Mankind Pharma Ltd and what does it indicate?
Mankind Pharma Ltd has a Price-to-Earnings (P/E) ratio of 51.46, which means investors are willing to pay ₹51.46 for every ₹1 of earnings. With an EPS of ₹46.27, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Mankind Pharma Ltd (MANKIND) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy